Skip to main content
Top
Published in: BMC Pediatrics 1/2023

Open Access 07-09-2023 | Pediatric Cancer | Case Report

​Occult extracranial malignancy after complete remission of pineal mixed germ cell tumors: a rare case report and literature review

Authors: Jun Liu, Luxiong Fang, Songtao Qi, Ye Song, Lei Han

Published in: BMC Pediatrics | Issue 1/2023

Login to get access

Abstract

Background

​Extracranial metastasis can occur in intracranial germ cell tumors (GCTs), but it is very rare. Recurrence or metastasis of non-germinomatous germ cell tumors (NGGCTs) is often accompanied by elevated tumor markers. ​Occult extracranial metastases or recurrences with negative markers are often difficult to detect in time, resulting in a very poor prognosis.

Case presentation

A 12-year-old boy was admitted to our institution with dizziness, headache, vomiting, and sleepiness. Magnetic resonance imaging (MRI) showed a pineal mass, accompanied by a significant increase in serum alpha-fetoprotein (AFP). The patient subsequently underwent total removal of the tumor. Pathology revealed that the tumor was a mixed GCT, consisting of mature teratoma, germinoma, and yolk sac tumor. Intracranial GCT achieved complete remission after intensive adjuvant chemotherapy and radiotherapy. Regular follow-up MRI revealed no recurrence of the intracranial tumor and continued monitoring of tumor markers revealed no abnormalities. ​Eight months later, the patient was readmitted due to progressive abdominal pain. Imaging and physical examination revealed abdominal occupation and lymphatic mass in the neck. He received salvage chemotherapy, anti-PD-1 immunotherapy, and palliative chemotherapy, but still developed multiple organ dysfunction syndromes (MODS) due to tumor progression and eventually died after one month.

Conclusions

​This profound case suggests that intracranial NGGCTs may develop occult extracranial malignancy, which can be very severe at the time of clinical symptoms and has an extremely poor prognosis. Therefore, in addition to tumor marker monitoring, regular follow-up with extracranial imaging may be warranted to detect extracranial tumors as early as possible, although perhaps not as frequently as with neuroimaging.
Literature
1.
go back to reference Jennings MT, Gelman R, Hochberg F. Intracranial germ-cell tumors: natural history and pathogenesis. J Neurosurg. 1985;63(2):155–67.CrossRefPubMed Jennings MT, Gelman R, Hochberg F. Intracranial germ-cell tumors: natural history and pathogenesis. J Neurosurg. 1985;63(2):155–67.CrossRefPubMed
2.
go back to reference Akai T, Iizuka H, Kadoya S, Nojima T. Extraneural metastasis of intracranial germinoma with syncytiotrophoblastic giant cells–case report. Neurologia medico-chirurgica. 1998;38(9):574–7.CrossRefPubMed Akai T, Iizuka H, Kadoya S, Nojima T. Extraneural metastasis of intracranial germinoma with syncytiotrophoblastic giant cells–case report. Neurologia medico-chirurgica. 1998;38(9):574–7.CrossRefPubMed
3.
go back to reference Itoyama Y, Kochi M, Yamashiro S, Yoshizato K, Kuratsu J, Ushio Y. Combination chemotherapy with cisplatin and etoposide for hematogenous spinal metastasis of intracranial germinoma–case report. Neurologia medico-chirurgica. 1993;33(1):28–31.CrossRefPubMed Itoyama Y, Kochi M, Yamashiro S, Yoshizato K, Kuratsu J, Ushio Y. Combination chemotherapy with cisplatin and etoposide for hematogenous spinal metastasis of intracranial germinoma–case report. Neurologia medico-chirurgica. 1993;33(1):28–31.CrossRefPubMed
4.
go back to reference Miyoshi Y, Omori M, Kobayashi N, Masuko T, Watanabe E, Date I. [A case of pineal pure germinoma metastasized to the lumbosacral extradural space 8 years after initial therapy. Case report and review of literature]. No shinkei geka Neurological surgery. 2006;34(7):745–52.PubMed Miyoshi Y, Omori M, Kobayashi N, Masuko T, Watanabe E, Date I. [A case of pineal pure germinoma metastasized to the lumbosacral extradural space 8 years after initial therapy. Case report and review of literature]. No shinkei geka Neurological surgery. 2006;34(7):745–52.PubMed
5.
go back to reference Watterson J, Priest JR. Control of extraneural metastasis of a primary intracranial nongerminomatous germ-cell tumor. Case report. J Neurosurg. 1989;71(4):601–4.CrossRefPubMed Watterson J, Priest JR. Control of extraneural metastasis of a primary intracranial nongerminomatous germ-cell tumor. Case report. J Neurosurg. 1989;71(4):601–4.CrossRefPubMed
6.
go back to reference Asanuma M, Aoyama T, Sakai K, Asano K, Uehara T, Hongo K. Hematogenous extraneural metastasis of the germinomatous component of a pineal mixed germ cell tumor. Brain Tumor Pathol. 2012;29(4):245–50.CrossRefPubMed Asanuma M, Aoyama T, Sakai K, Asano K, Uehara T, Hongo K. Hematogenous extraneural metastasis of the germinomatous component of a pineal mixed germ cell tumor. Brain Tumor Pathol. 2012;29(4):245–50.CrossRefPubMed
7.
go back to reference Ayyanar K, Blackman SC, Chordas C, Frazier L, Kieran MW. Metachronous mediastinal seminoma occurring after intracranial germinoma in an adolescent. J Pediatr Hematol Oncol. 2009;31(11):861–4.CrossRefPubMed Ayyanar K, Blackman SC, Chordas C, Frazier L, Kieran MW. Metachronous mediastinal seminoma occurring after intracranial germinoma in an adolescent. J Pediatr Hematol Oncol. 2009;31(11):861–4.CrossRefPubMed
8.
go back to reference Silva VB, Azevedo AL, Costa IM, Mafra MS, Passos-Coelho JL, Bravo-Marques JM. Mixed testicular germ cell tumour in a patient with previous pineal germinoma. J Neurooncol. 2011;101(1):125–8.CrossRefPubMed Silva VB, Azevedo AL, Costa IM, Mafra MS, Passos-Coelho JL, Bravo-Marques JM. Mixed testicular germ cell tumour in a patient with previous pineal germinoma. J Neurooncol. 2011;101(1):125–8.CrossRefPubMed
9.
go back to reference Nishikawa R, Matsutani M. Immunohistochemical analysis of p53 and p21(WAF1/Cip1) expression in primary intracranial germ cell tumors. NeuroSurg Focus. 1998;5(1):e2.CrossRefPubMed Nishikawa R, Matsutani M. Immunohistochemical analysis of p53 and p21(WAF1/Cip1) expression in primary intracranial germ cell tumors. NeuroSurg Focus. 1998;5(1):e2.CrossRefPubMed
10.
go back to reference Lobo J, Alzamora MA, Guimaraes R, Cantante M, Lopes P, Braga I, Mauricio J, Jeronimo C, Henrique R. p53 and MDM2 expression in primary and metastatic testicular germ cell tumors: Association with clinical outcome. Andrology. 2020;8(5):1233–42.CrossRefPubMed Lobo J, Alzamora MA, Guimaraes R, Cantante M, Lopes P, Braga I, Mauricio J, Jeronimo C, Henrique R. p53 and MDM2 expression in primary and metastatic testicular germ cell tumors: Association with clinical outcome. Andrology. 2020;8(5):1233–42.CrossRefPubMed
11.
go back to reference Akizuki K, Sekine M, Kogure Y, Kameda T, Shide K, Koya J, Kamiunten A, Kubuki Y, Tahira Y, Hidaka T, et al. TP53 and PTEN mutations were shared in concurrent germ cell tumor and acute megakaryoblastic leukemia. BMC Cancer. 2020;20(1):5.CrossRefPubMedPubMedCentral Akizuki K, Sekine M, Kogure Y, Kameda T, Shide K, Koya J, Kamiunten A, Kubuki Y, Tahira Y, Hidaka T, et al. TP53 and PTEN mutations were shared in concurrent germ cell tumor and acute megakaryoblastic leukemia. BMC Cancer. 2020;20(1):5.CrossRefPubMedPubMedCentral
12.
go back to reference Schneider K, Zelley K, Nichols KE, Garber J. Li-Fraumeni Syndrome. In: GeneReviews(®) edn. Edited by Adam MP, Mirzaa GM, Pagon RA, Wallace SE, Bean LJH, Gripp KW, Amemiya A. Seattle (WA): University of Washington, Seattle Copyright © 1993–2022, University of Washington, Seattle. GeneReviews is a registered trademark of the University of Washington, Seattle. All rights reserved. 1993. Schneider K, Zelley K, Nichols KE, Garber J. Li-Fraumeni Syndrome. In: GeneReviews(®) edn. Edited by Adam MP, Mirzaa GM, Pagon RA, Wallace SE, Bean LJH, Gripp KW, Amemiya A. Seattle (WA): University of Washington, Seattle Copyright © 1993–2022, University of Washington, Seattle. GeneReviews is a registered trademark of the University of Washington, Seattle. All rights reserved. 1993.
13.
go back to reference de Andrade KC, Khincha PP, Hatton JN, Frone MN, Wegman-Ostrosky T, Mai PL, Best AF, Savage SA. Cancer incidence, patterns, and genotype–phenotype associations in individuals with pathogenic or likely pathogenic germline TP53 variants: an observational cohort study. Lancet Oncol. 2021;22(12):1787–98.CrossRefPubMedPubMedCentral de Andrade KC, Khincha PP, Hatton JN, Frone MN, Wegman-Ostrosky T, Mai PL, Best AF, Savage SA. Cancer incidence, patterns, and genotype–phenotype associations in individuals with pathogenic or likely pathogenic germline TP53 variants: an observational cohort study. Lancet Oncol. 2021;22(12):1787–98.CrossRefPubMedPubMedCentral
14.
go back to reference Olivier M, Goldgar DE, Sodha N, Ohgaki H, Kleihues P, Hainaut P, Eeles RA. Li-Fraumeni and related syndromes: correlation between tumor type, family structure, and TP53 genotype. Cancer Res. 2003;63(20):6643–50.PubMed Olivier M, Goldgar DE, Sodha N, Ohgaki H, Kleihues P, Hainaut P, Eeles RA. Li-Fraumeni and related syndromes: correlation between tumor type, family structure, and TP53 genotype. Cancer Res. 2003;63(20):6643–50.PubMed
15.
go back to reference Fonseca A, Faure-Conter C, Murray MJ, Fangusaro J, Bailey S, Goldman S, Khatua S, Frappaz D, Calaminus G, Dhall G et al. Pattern of Treatment Failures in Central Nervous System Non-Germinomatous Germ Cell Tumors (CNS-NGGCT): A Pooled Analysis of Clinical Trials. Neuro-oncology 2022. Fonseca A, Faure-Conter C, Murray MJ, Fangusaro J, Bailey S, Goldman S, Khatua S, Frappaz D, Calaminus G, Dhall G et al. Pattern of Treatment Failures in Central Nervous System Non-Germinomatous Germ Cell Tumors (CNS-NGGCT): A Pooled Analysis of Clinical Trials. Neuro-oncology 2022.
Metadata
Title
​Occult extracranial malignancy after complete remission of pineal mixed germ cell tumors: a rare case report and literature review
Authors
Jun Liu
Luxiong Fang
Songtao Qi
Ye Song
Lei Han
Publication date
07-09-2023

Other articles of this Issue 1/2023

BMC Pediatrics 1/2023 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine